Enhancing Tyrosine Kinase Inhibitor Success in NSCLC Through Maximizing Potent Activity Against Exon20 Insertion (Ex20ins) Mutations with a Novel, Oral EGFR Inhibitor

Time: 4:00 pm
day: Day One


  • Developing an EGFR inhibitor which targets Ex20ins mutations with high potency while sparing the WT EGFR activity
  • Overcoming toxicities related to inhibition of wild-type EGFR, including rash and diarrhea, which can compromise the use of EGFR Ins20 inhibitors
  • Presenting the latest clinical data from Cullinan’s phase 2a study with the selective candidate, CLN-081